Product Reports Resources Pricing Login Book a demo

Kallyope

Biotech & Life Sciences · New York City, United States · Founded 2015

Kallyope is a biotechnology startup based in New York City that operates in the healthcare sector. The company's primary focus is on the exploration and understanding of the complex network of interconnections between the gut, brain, and other organs in the human body. Kallyope's mission is to develop transformative therapeutics for a range of challenging diseases including diabetes, obesity, gut disorders, inflammatory diseases, migraines, allergies, and more. The company serves a broad client base, primarily within the healthcare and pharmaceutical industries. These clients are typically organizations seeking innovative solutions for the treatment of various diseases. Kallyope's business model revolves around the use of its proprietary Klarity™ Platform. This platform integrates a range of leading technologies to discover and translate gut-brain biology, which is then used to develop new therapeutics. Kallyope generates revenue through the development and commercialization of these therapeutics. The company's income comes from the sales of these treatments to healthcare providers and pharmaceutical companies. Additionally, Kallyope may also generate income through partnerships with other organizations in the healthcare sector, licensing its technologies, or through research grants. The company prides itself on its culture of curiosity and connection, and its commitment to discovering new solutions to the world's most challenging diseases. Kallyope's operations are rooted in New York City, a hub for biotechnology innovation. Keywords: Biotechnology, Healthcare, Gut-Brain Biology, Therapeutics, Disease Treatment, Klarity™ Platform, Diabetes, Obesity, Inflammatory Diseases, New York City.

Valuation $1–2.5B
Revenue $1–10M
Headcount <100
Total funding $100–500M
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Kallyope and the history behind them.
Power Law Unicorn$1–10B valuation tier

Investors

19 investors on Kallyope's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 1 investor entered at this stage
Bill & Melinda Gates Foundation
Series A 10 investors entered at this stage
Illumina
Lux Capital
Polaris Partners
The Column Group
Tony Evnin
Illumina Ventures
Euclidean Capital
Two Sigma Ventures
Alexandria Venture Investments
Bill Gates
Series B+ 8 investors entered at this stage
Casdin Capital
Greenspring Associates
Mubadala Capital
Hartford HealthCare Endowment
StepStone Group
DNS Capital
Tao Capital Partners
Parkwood

Global footprint

Where Kallyope has talent and traffic

Workforce by country
2 countries with
team presence
🇺🇸 United States98.2%
🇮🇶 Iraq1.8%
2 countries shown
Web traffic by country
4.8K monthly visits
across markets
🇺🇸 United States95.8%
🇮🇳 India2.1%
🇯🇵 Japan0%
Top 3 markets shown

Talent graph

The shape of Kallyope's talent

Dealroom maps Kallyope's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

9 standout operatorsDealroom-flagged across the org
1 AI specialistincl. 1 core researchers
56 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Kallyope's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$9M patent portfolio · 13 active families

Estimated portfolio value
$9M
0.72% of valuation · 38.2× smaller than top peer Translate Bio ($336M)
13 active patent families
Where Kallyope innovates BiochemistryCell biologyDiseaseGeneralized infectionGut barrier

Where Kallyope concentrates vs peers

Each axis is a top-10 topic across Kallyope and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Kallyope

An AI-synthesized read of the highest-engagement posts about Kallyope on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Kallyope on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles